Keyphrases
Metastatic Renal Cell Carcinoma (mRCC)
100%
Poor Risk
100%
Low-risk Patients
100%
Clinical Database
100%
Memorial Sloan-Kettering Cancer Center
55%
Risk Model
33%
Targeted Therapy
22%
Patient Demographics
22%
C-index
22%
Prospective Clinical Trial
22%
Clinical Benefit
22%
Objective Response Rate
22%
Prognostic Model
22%
International Metastatic Renal Cell Carcinoma Database Consortium
22%
Adverse Events
11%
Median Overall Survival
11%
Median Progression-free Survival
11%
Improved Outcomes
11%
Retrospective Analysis
11%
Baseline Characteristics
11%
Phase III Clinical Trial
11%
Patient Experience
11%
Clinical Trial Data
11%
Phase II Clinical Trial
11%
Discriminative Ability
11%
Alternative Treatment Strategies
11%
Overall Survival Progression-free Survival
11%
Prognostic Performance
11%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Kidney Metastasis
100%
Malignant Neoplasm
83%
Progression Free Survival
33%
Overall Survival
33%
Adverse Event
16%